Zim Laboratories Ltd

Zim Laboratories, a microcap pharmaceutical company, has reported a negative performance in the second quarter of fiscal year 2024-2025. Its profit before tax and after tax have declined by -59.20% and -42.7% respectively compared to the same period last year. The company's interest costs have increased and its operating cash flow has been consistently falling. Non-operating income is a significant portion of its profits, raising concerns about sustainability.

Zim Laboratories, a microcap pharmaceutical company, has reported a negative performance in the quarter ending June 2024, with a score of -14. However, the company's PAT and net sales have shown growth. Concerns include falling operating cash flow, increased interest cost, and reliance on borrowings. Investors should carefully analyze the financials before making any decisions.

Zim Laboratories, a microcap pharmaceutical company, has announced its financial results for the quarter ending December 2023. Despite a negative performance, the company has shown improvements in its debt-equity ratio and debtors turnover ratio. However, there are concerns regarding a decline in profit and an increase in interest cost. Investors should carefully consider these factors before making any investment decisions.

Zim Laboratories, a microcap pharmaceutical company, reported a 27.27% growth in net sales and a significant improvement in consolidated net profit for the quarter ended September 2023. However, the company's stock call is currently 'Strong Sell' and its financial performance has been negative. Investors should carefully consider these factors before making any investment decisions.